Previous 10 | Next 10 |
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company’s management team will host a conference call to review operating results for the first qua...
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity “Horizons in Oncology” virtual confe...
Strong balance sheet: Approximately $110 million in cash and cash equivalents as of March 31, 2021 1 Company remains on-track for potential product approvals in US in August 2021 and in Europe in early 2022 Sesen Bio (Nasdaq: SESN ), a late-stage clinical...
Analysts Like These Penny Stocks If you’re looking for penny stocks to buy right now, you’re not alone. The stock market as a whole is trading higher this week, thanks to economic data on Friday. Though the market was closed, that didn’t prevent the weekly jobs figu...
Though being an extremely volatile stock, Sesen has an intriguing pipeline of medicines. As a potential blockbuster, Vicineum already passed its Phase 3 trial with ease. As it's riding an upcoming approval, I believe Sesen will embark on a vigorous rally. For further details...
Sesen Bio (SESN) announces that the Investigational New Drug (or IND) application for Vicineum submitted by the company's partner, Qilu Pharmaceutical, was approved ahead of the original timeline of April 2021.Vicineum is used for the treatment of BCG-unresponsive non-muscle in...
Support.com (SPRT) +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU) +17% as Canadian Pacific to buy the company fo...
IND approval triggers $3 million milestone payment to Sesen Bio Product market application expected to be submitted to the National Medical Product s Administration in 2022 with potential approval in 2023 Sesen Bio (Nasdaq: SESN ), a late-stage clinic...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to three new employees in connection with the commencement of their employ...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...